News and Announcements
Only 2 Days Left in the Shivom Presale!
- Published April 19, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Key Takeaways:
- Shivom’s OmiX Presale closes April 22nd, 12PM GMT
- Can’t contribute to the Presale- You can still earn up to 8% bonus on the purchase of first 15 000 ETH
Don’t miss your chance, contribute now!
This is a quick reminder that the OmiX Presale is ending soon! April 22nd, 2018 is the last day and the sale will close at 12PM GMT.
If you have not yet contributed to our presale there’s still time and rewards to be earned! You can still earn up to 8% bonus on the purchase of first 15 000 ETH. This bonus started at 10% on April 16th and will keep decreasing by 1% each day. It is also your last chance to buy OmiX tokens at 1 ETH = 7000 OmiX.
We’d like to remind you that:
Registration for Shivom’s Presale is completely secure – we are using the most secure platform for investing in our OmiX token, so you don’t have to worry about ICO scams. Make sure to complete your KYC on our platform in order to receive OmiX tokens in your wallet at the end of the sale.
For more details see our step by step guide:
https://medium.com/@
Don’t miss earning your bonuses as this will expire on the last day of the presale – April 22nd, 2018.
If you haven’t yet been able to register, complete your KYC or purchase tokens, do so now on our tokensale dashboard at https://tokensale.shivom.io/.
There are also additional discounts to be earned by sending your unique referral link from the platform to all your contacts.
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
